CTSO
Cytosorbents Corporation
CTSO has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
CTSO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
CTSO's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CTSO PE Valuation
CTSO has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CTSO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
CTSO has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CTSO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.80 | -$2.40 |
| Q1 2026 | -$3.80 | +$1.80 |
| Q4 2025 | -$2.60 | +$5.00 |
| Q3 2025 | -$3.60 | +$3.60 |
| Q2 2025 | -$3.40 | +$7.20 |
| Q1 2025 | -$5.60 | +$6.20 |
| Q4 2024 | -$7.60 | +$5.20 |
| Q3 2024 | -$7.20 | +$3.60 |
CTSO is still losing money, but far less than before: $5.80 per share over the past year, against $18.40 at its worst in late 2022.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CTSO on earnings quality, reporting a profit while its opponent remains loss making.
CTSO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $9.6M | +0.2% |
| Q1 2026 | $8.9M | +1.6% |
| Q4 2025 | $9.2M | +42% |
| Q3 2025 | $9.5M | +1% |
| Q2 2025 | $9.6M | -2.8% |
| Q1 2025 | $8.7M | -11% |
| Q4 2024 | $6.5M | -25% |
| Q3 2024 | $9.4M | +6.6% |
CTSO's revenue has grown year over year for four quarters in a row: $10M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -27% | +10 points |
| Q1 2026 | -34% | +10 points |
| Q4 2025 | -47% | +15 points |
| Q3 2025 | -30% | +17 points |
| Q2 2025 | -38% | -3 points |
| Q1 2025 | -45% | +5.8 points |
| Q4 2024 | -62% | +47 points |
| Q3 2024 | -47% | +37 points |
CTSO's operating margin was −27% last quarter, up 10 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CTSO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CTSO on profitability, with a higher operating margin.
CTSO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$597K | +$949.9K |
| Q1 2026 | -$1.2M | +$2.3M |
| Q3 2025 | -$2.6M | -$132.8K |
| Q2 2025 | -$1.5M | +$3.2M |
| Q1 2025 | -$3.5M | +$1.4M |
| Q3 2024 | -$2.5M | +$2.9M |
| Q2 2024 | -$4.8M | +$1.9M |
| Q1 2024 | -$4.9M | -$1.3M |
CTSO has burned cash in almost every quarter: −$9M over the past year, against −$12M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CTSO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTSO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3.4K shares |
| 1 year | -6.5% | -218K shares |
| 3 years | +43% | +940K shares |
| 5 years | +45% | +974K shares |
| Available history | +94% | +1.5M shares |
CTSO has the edge over NVO on shareholder dilution, with a more favorable share count trend.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CTSO Net Leverage
CTSO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CTSO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 31.3 | Neutral |
CTSO's weekly RSI is 40 (neutral) and its Stochastic is 31 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CTSO PE vs Healthcare Sector
CTSO has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CTSO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 18% above |
| 20 week MA | $6.09 | 12% below |
| 50 week MA | $9.78 | 45% below |
| 100 week MA | $14.6 | 63% below |
| 200 week MA | $25.4 | 79% below |
CTSO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 79% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CTSO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.6 | $166.2 | +117% |
| 2021 | $166.2 | $89.0 | -46% |
| 2022 | $89.0 | $28.0 | -69% |
| 2023 | $28.0 | $22.2 | -21% |
| 2024 | $22.2 | $18.8 | -15% |
| 2025 | $18.8 | $13.6 | -28% |
| 2026 YTD | $13.6 | $5.37 | -61% |
CTSO has finished five years in a row lower, and it's down 61% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CTSO on returns for 2026, with the stronger performance.